Egg-derived proteins and formulation excipients

Egg-derived proteins and formulation excipients refer to a group of substances present in pharmaceutical products, particularly vaccines, either as intentional additives or residual manufacturing byproducts. Egg-derived proteins, such as ovalbumin, ovomucoid, and ovotransferrin, are often found in vaccines produced using embryonated chicken eggs, such as those for influenza and yellow fever (CDC, 2023; WHO, 2022). Formulation excipients include a wide range of substances like stabilizers (e.g., gelatin, sucrose), surfactants (e.g., polysorbate 80), and preservatives (e.g., thimerosal) used to ensure the safety and efficacy of the drug product (FDA, 2021). While these components are generally safe for the majority of the population, they are significant in clinical practice due to their potential to trigger hypersensitivity or anaphylactic reactions in susceptible individuals, particularly those with severe egg allergies (Greenhawt et al., 2018). Consequently, they are monitored as safety parameters rather than targeted for therapeutic effect. Understanding the profile of these excipients is essential for risk assessment in patients with known allergies and for the development of alternative, egg-free manufacturing platforms like cell-culture or recombinant technologies.

Other names

Egg proteinsVaccine excipientsOvalbuminPharmaceutical additivesResidual egg proteins

These substances are not therapeutic targets; they function as stabilizers or are residual manufacturing byproducts that can induce IgE-mediated hypersensitivity reactions in sensitized individuals (Greenhawt et al., 2018).